NCT05171660 2026-02-17
Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 3 Active not recruiting
Clinical Trials
10 trialsNCT07306663 2025-12-29
ESO-Nanjing7
Jiangsu Cancer Institute & Hospital
Phase 3 Active not recruiting
NCT05177068 2025-10-02
Conversion Therapy of Fruquintinib in Combination With Sintilimab and SOX in Unresectable Gastric Cancer
Henan Cancer Hospital
Phase 2 Active not recruiting
NCT05481476 2025-09-04
Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic Cancer
Sun Yat-sen University
Phase 2 Active not recruiting
NCT03869034 2024-12-03
HAICPD1-HCC
Sun Yat-sen University
Phase 2 Active not recruiting
NCT04940546 2024-12-03
Neoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in PMMR/MSS CRLM Patients
Sun Yat-sen University
Phase 1/2 Active not recruiting
NCT06667050 2024-10-31
CAPOX Plus Sintilimab and Bevacizumab Biosimilar (IBI305) for Neoadjuvant Treatment of Locally Advanced Gastric Cancer
West China Hospital
Phase 2 Active not recruiting
NCT04220944 2024-08-01
Combined Locoregional Treatment With Immunotherapy for Unresectable HCC.
Shanghai Zhongshan Hospital
Phase 1 Active not recruiting
NCT04906044 2023-11-18
STARS-RC03
The First Hospital of Jilin University
Phase 1 Active not recruiting
NCT04304209 2023-02-01
Pd1 Antibody Sintilimab ± Chemoradiotherapy for Locally Advanced Rectal Cancer
Sun Yat-sen University
Phase 2 Active not recruiting